^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Natera

    i
    Other names: Natera | Natera Inc | Natera Inc. | Natera, Inc. | Gene Security Network | Gene Security Network Inc | Gene Security Network Inc. | Gene Security Network, Inc.
    Related tests:
    Evidence

    News

    23d
    Signatera™ MRD Identifies Breast Cancer Patients Who Can Forgo Surgery (Natera Press Release)
    "Natera, Inc...today announced a publication in Clinical Cancer Research showing that Signatera was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pET), without surgery." "
    Clinical
    |
    Signatera™
    1m
    Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers (Natera Press Release)
    "Natera...today announced two peer-reviewed publications highlighting the clinical utility of Signatera, its personalized, tumor-informed circulating tumor DNA (ctDNA) assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC)."
    Clinical
    |
    Signatera™
    2ms
    Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation (Natera Press Release)
    "Natera, Inc...today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026."
    Clinical data
    3ms
    A Randomized Study of Rejection Surveillance with Donor-Derived Cell-Free DNA versus Endomyocardial Biopsy After Heart Transplant (ACES-EMB): Rationale, Design and Patient Characteristics (ISHLT 2026)
    P=N/A | "Study protocol adherence is high and no relevant study-related safety concerns have been identified to date.Conclusion ACES-EMB is the first randomized multicenter study to compare surveillance after HT with dd-cfDNA to EMB-based care. We anticipate the results of this study directly impact clinical care of heart transplant recipients and guidelines recommendations."
    Clinical
    4ms
    Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer (Natera Press Release)
    "Natera, Inc. (NASDAQ: NTRA)...today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year."
    New P3 trial
    |
    Signatera™
    4ms
    I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer (Natera Press Release)
    "Natera, Inc...together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the I-SPY 2 trial in Nature Communications."
    Clinical
    |
    Signatera™
    4ms
    Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer (Natera Press Release)
    "Natera...together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG), today announced initial translational research results from the international randomized Phase III PALLAS study." "
    New P3 trial
    |
    Signatera™
    5ms
    New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting (Natera Press Release)
    "Natera...announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies."
    Clinical data
    |
    Signatera™
    5ms
    Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium (Natera Press Release)
    "Natera, Inc...today announced that at least twelve abstracts highlighting Signatera will be shared at the 2025 San Antonio Breast Cancer Symposium (SABCS)"
    Clinical data
    |
    Signatera™
    5ms
    NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy. (ASCO-GI 2026)
    P2 | "Funded by Regeneron, Natera, Inc., NSABP Foundation, Inc. Clinical Trial Registration Number: NCT07058012 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."
    Clinical • P2 data • Minimal residual disease
    |
    Libtayo (cemiplimab-rwlc)
    5ms
    NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America). (ASCO-GI 2026)
    P2/3 | "Funded by U.S. National Institutes of Health, U.S. National Institutes of Health, U.S. National Institutes of Health, U.S. National Institutes of Health, Natera, Inc. Clinical Trial Registration Number: NCT05174169 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."
    Clinical
    6ms
    Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT (Natera Press Release)
    " Natera...today announced it will expand its Fetal Focus test to cover 20 genes, marking a major advancement in single-gene noninvasive prenatal testing (sgNIPT). Building on the success of the initial Fetal Focus 5-gene test, launched in August, the new expanded panel will launch in Q4 2025."
    Clinical